Por favor, use este identificador para citar o enlazar este Item:http://hdl.handle.net/20.500.12105/20233
Título
Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study
Autor(es)
Laguno, M | Von Wichmann, MA | Van den Eynde, E | Navarro, J | Cifuentes Luna, Carmen | Murillas Angoiti, Javier | Veloso, S | Martinez-Rebollar, M | Guardiola, JM | Jou, A | Gomez-Sirvent, J. L | Cervantes, M | Pineda, JA | Lopez-Calvo, S | Carrero, A | Montes, ML | Deig, Elisabeth | Tapiz, A | Ruiz-Mesa, JD | Cruceta, A | de Lazzari, Ellsa | Mallolas, J
Fecha de publicación
2016-12
Cita
Laguno M, Von Wichmann MA, Van Den Eynde E, Navarro J, Cifuentes Luna C, Murillas Angoiti J, et al. Boceprevir plus pegylated interferon/ribavirin to re-treat hepatitis C virus genotype 1 in HIV-HCV co-infected patients: final results of the Spanish BOC HIV-HCV Study. Int J Infect Dis. 2016 Dec;53:46-51. Epub 2016 Nov 1.
Idioma
Inglés
Tipo de documento
research article
Resumen
Introduction: Boceprevir (BOC) was one of the first oral inhibitors of hepatitis C virus (HCV) NS3 protease to be developed. This study assessed the safety and efficacy of BOC + pegylated interferon-alpha 2a/ribavirin (PEG-IFN/RBV) in the retreatment of HIV-HCV co-infected patients with HCV genotype 1. Methods: This was a phase III prospective trial. HIV-HCV (genotype 1) co-infected patients from 16 hospitals in Spain were included. These patients received 4 weeks of PEG-IFN/RBV (lead-in), followed by response-guided therapy with PEG-IFN/RBV plus BOC (a fixed 44 weeks was indicated in the case of cirrhosis). The primary endpoint was the sustained virological response (SVR) rate at 24 weeks post-treatment. Efficacy and safety were evaluated in all patients who received at least one dose of the study drug. Results: From June 2013 to April 2014, 102 patients were enrolled, 98 of whom received at least one treatment dose. Seventy-three percent were male, 34% were cirrhotic, 23% had IL28b CC, 65% had genotype 1a, and 41% were previous null responders. The overall SVR rate was 67%. Previous null-responders and cirrhotic patients had lower SVR rates (57% and 51%, respectively). Seventy-six patients (78%) completed the therapy scheme; the most common reasons for discontinuation were lack of response at week 12 (12 patients) and adverse events (six patients). Conclusions: Response-guided therapy with BOC in combination with PEG-IFN/RBV led to an overall SVR rate of 67%, but an SVR rate of only 51% in patients with cirrhosis. The therapy was generally well tolerated. Although the current standards of care do not include BOC + PEG-IFN/RBV, the authors believe that this combination can be beneficial in situations where new HCV direct antiviral agent interferonfree therapies are not available yet.
Palabras clave
MESH
Viral Nonstructural Proteins | Genotype | Hepacivirus | Retreatment | Polyethylene Glycols | Spain | Adult | Antiviral Agents | Hepatitis C | Humans | Drug Therapy, Combination | Middle Aged | Recombinant Proteins | HIV Infections | Male | Prospective Studies | Female | Coinfection | Treatment Outcome | Proline | Interferon-alpha | Ribavirin
DECS
Prolina | Resultado del Tratamiento | Coinfección | Polietilenglicoles | Interferón-alfa | Femenino | Infecciones por VIH | Masculino | Quimioterapia Combinada | Hepatitis C | Humanos | Persona de Mediana Edad | Estudios Prospectivos | Genotipo | Proteínas Recombinantes | Proteínas no Estructurales Virales | Antivirales | Adulto | Ribavirina | Hepacivirus | Retratamiento | España
Versión en línea
DOI
Aparece en las colecciones
Acceso a texto completo